

NVP-BHG712

Catalog No: tcsc0469



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

940310-85-0

Formula:

$C_{26}H_{20}F_3N_7O$

Pathway:

Protein Tyrosine Kinase/RTK

Target:

Ephrin Receptor

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

503.48

Product Description

NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows


activity against c-Raf, c-Src and c-Abl with IC₅₀ of 0.395 μ M, 1.266 μ M and 1.667 μ M, respectively.

IC₅₀ value: 25 nM(EC₅₀)

Target: EphB4 receptor; c-Raf; c-Src

in vitro: NVP-BHG712 treatment also dose dependently leads to the inhibition of RTK autophosphorylation in stable transfected A375 melanoma cells with EC₅₀ of 25 nM and 4.2 μ M for EphB4 and VEGFR2, respectively [1].

in vivo: In a growth factor-induced angiogenesis model, NVP-BHG712 (3 mg/kg, p.o) significantly suppresses VEGF stimulated tissue formation and vascularization by inhibiting EphB4 forward signaling. Furthermore, NVP-BHG712 (10 mg/kg/kg, p.o.) potently reverses VEGF enhanced tissue formation and vessel growth. NVP-BHG712 (3 mg/kg, p.o.) shows a long lasting exposure with concentrations around 10 μ M in plasma as well as in lung and liver tissue for up to 8 hours, and thus results in a long lasting inhibition of EphB4 kinase activity in mice [1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!